Table 4 Clinical trials of endocrine therapy combined with agents targeting Hippo pathway for reference
From: Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer
Agents | Study phase | Outcome | NCT number | Possible mechanisms | |
|---|---|---|---|---|---|
Hippo pathway | Endocrine therapy | ||||
Atorvastatin | Letrozole, Fulvestrant | Phase 2 | No results available | NCT02958852 | Stains inhibits YAP/TAZ nuclear localization, and suppressed the self-renewal capability of cancer stem cells via opposing nuclear TAZ activity [140] Metformin inhibits YAP nuclear localization [141] |
Metformin, Simvastatin | Fulvestrant | Phase 2 | No results available | NCT03192293 | |
Metformin | Toremifene | Phase 2 | No results available | NCT02506790 | |
Metformin | Fulvestrant | Phase 2 | No results available | NCT04300790 | |
Metformin | Everolimus, Exemestane | Phase 2 | The clinical benefit rate was 54.5% | NCT01627067 | |